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Background: Yarrowia lipolytica efficiently metabolizes and assimilates hydrophobic compounds such as n-alkanes
and fatty acids. Efficient substrate uptake is enabled by naturally secreted emulsifiers and a modified cell surface
hydrophobicity and protrusions formed by this yeast. We were examining the potential of recombinant Y. lipolytica
as a biocatalyst for the oxidation of hardly soluble hydrophobic steroids. Furthermore, two-liquid biphasic culture
systems were evaluated to increase substrate availability. While cells, together with water soluble nutrients, are
maintained in the aqueous phase, substrates and most of the products are contained in a second water-immiscible
organic solvent phase.
Results: For the first time we have co-expressed the human cytochromes P450 2D6 and 3A4 genes in Y. lipolytica
together with human cytochrome P450 reductase (hCPR) or Y. lipolytica cytochrome P450 reductase (YlCPR). These
whole-cell biocatalysts were used for the conversion of poorly soluble steroids in biphasic systems.
Employing a biphasic system with the organic solvent and Y. lipolytica carbon source ethyl oleate for the whole-cell
bioconversion of progesterone, the initial specific hydroxylation rate in a 1.5 L stirred tank bioreactor was further
increased 2-fold. Furthermore, the product formation was significantly prolonged as compared to the aqueous
system.
Co-expression of the human CPR gene led to a 4-10-fold higher specific activity, compared to the co-
overexpression of the native Y. lipolytica CPR gene. Multicopy transformants showed a 50-70-fold increase of activity
as compared to single copy strains.
Conclusions: Alkane-assimilating yeast Y. lipolytica, coupled with the described expression strategies, demonstrated
its high potential for biotransformations of hydrophobic substrates in two-liquid biphasic systems. Especially organic
solvents which can be efficiently taken up and/or metabolized by the cell might enable more efficient
bioconversion as compared to aqueous systems and even enable simple, continuous or at least high yield long
time processes.
Keywords: Yarrowia lipolytica, Biphasic sytem, Cytochrome P450, Steroid, Whole-cell bioconversionIntroduction
Cytochrome P450s (CYPs) are a large, ubiquitous family
of heme-containing monooxygenases that are respon-
sible for the oxidative metabolism of a wide variety of
drugs, environmental chemicals and endogenous com-
pounds, such as steroids, prostaglandins and fatty
acids [1].* Correspondence: a.glieder@tugraz.at
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reproduction in any medium, provided the orMost cytochrome P450 systems are composed of a
monooxygenase and one or two additional proteins,
constituting an electron transfer chain. Genes encoding
these components are either expressed individually or
linked resulting in self sufficient CYPs. To some extent,
the natural electron transport chain from NAD(P)H to
the heme containing cytochrome P450 can be replaced
by either homologues or different proteins with similar
function e.g. flavodoxin and flavodoxin reductase to sup-
port catalytic activity [2]. Therefore, the activity of CYPs
is not only determined by its abundance, but also by thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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possibly by their molar ratio.
Eukaryotic CYPs are membrane associated and many
of those are located on the cytosolic side of the endo-
plasmic reticulum membrane. However, several import-
ant CYPs such as the vitamin D3 25-hydroxylase
CYP27B1 are also associated to mitochondrial mem-
brane [4]. In mammalian cells, expression takes place in
different tissues, but the highest levels are found in the
liver, where CYPs have the principal function to intro-
duce an oxygen atom into hydrophobic substrates. The
increased hydrophilicity of the product facilitates its
elimination from the mammalian body.
Several genes of xenobiotic-metabolizing CYPs are
expressed in human liver, among which CYP1A2,
CYP2C9, CYP2C19, CYP2D6 and CYP3A4 appear to be
most commonly responsible for drug metabolism [5].
The relative importance for drug metabolism is reflected
in the abundance of these enzymes, e.g., CYP3A4 being
most abundant with ~ 30% of total CYP in liver cells, and
the preference to bind and/or metabolize chemicals with
structures commonly found in drugs, e.g., CYP2D6 pre-
ferentially binds widely used drugs with basic amine
functions [3].
Many of these drug-metabolizing CYPs are subject to
polymorphisms, duplications, and differential expression
levels, which gives rise to wide variation in pharmaco-
kinetics profiles. This makes CYPs highly important to
the pharmaceutical industry, where human drug meta-
bolites are essential for drug development and analysis.
In order to provide sufficient amounts of human
CYPs, several recombinant expression systems have been
investigated in the past 20 years, from the more compli-
cated and expensive mammalian [6] and Baculovirus-
infected insect cell system [7] to the “simpler” expression
host Escherichia coli. Since the first functional expres-
sion of mammalian CYPs in bakers’s yeast Saccharo-
myces cerevisiae was demonstrated in the mid 80s [8,9],
in recent years, the focus shifted more and more to yeast
systems, which combine the ease of handling of prokary-
otic systems with the sub-cellular structure of eukaryotic
systems reassembling a more natural environment.
Mammalian CYP genes have been expressed, e.g., in the
yeasts S. cerevisiae [8-14], P. pastoris [15,16], S. pombe
[17-19], and Y. lipolytica [20-22]. Frequently, whole-cells
were used for drug metabolite synthesis to deal with in-
herent stability problems of human CYP enzymes and
regeneration of NADPH.
Most of the typical substrates for CYPs are very hydro-
phobic and most probably enter the enzyme’s active site
via biological membranes. This also explains why specific
activities of truncated and soluble human CYPs are lower
than those of their native membrane bound counterparts
[23]. Another obstacle in performing bioconversions withhydrophobic substrates is their very low solubility in the
aqueous phase, which limits cellular uptake and thus
overall biotransformation performance. Investigations
showed that the substrates have to be added in concen-
trations above the solubility limit to achieve efficient bio-
transformation. To ensure a homogenous suspension,
the substrates have to be dissolved at high concentration
in an organic solvent and quickly added to the aqueous
solution [24].
However, there are several approaches to increase sub-
strate availability. The addition of water-miscible organic
solvents or detergents has been tested [17], which may
results in a drastic increase of substrate solubility. Some
solvents and most of the detergents, however, have a
strong impact on cell membranes, compromising cell in-
tegrity and viability, and thus biocatalyst functionality.
In a more sophisticated approach, water-soluble cyclo-
dextrins, toroid-shaped cyclic oligosaccharids, have been
used to capture hydrophobic substances in their cavities,
thereby increasing their apparent solubility. This approach
has been successfully used with Mycobacterium sp. [25],
but seems to have toxic effects on yeast cells [17].
Biphasic systems consisting of an organic and an aque-
ous phase, represent a valuable tool for the biotransform-
ation of hydrophobic substrates [26-32]. The organic
phase regulates the substrate and product concentration
in the aqueous phase, allowing high overall concentra-
tions of otherwise toxic hydrophobic substrates. Further-
more, such a system can be used to avoid inhibition
effects by substrate and/or product and can help to guide
equilibrium reactions into the desired direction enhan-
cing stereoselectivity. A crucial step is the choice of the
organic phase depending on different parameters, includ-
ing toxic or inhibitory effects of the solvent on the cells
as well as substrate and product solubility [31,32].
Our studies have been focused on Y. lipolytica which is
naturally adapted to such two-phase systems. Y. lipolytica
is often isolated from biphasic environments like dairy
products rich in lipids [33] or oil-polluted soil and water
[34,35]. Applications of Y. lipolytica include bioremedi-
ation of diesel-contaminated soils [36] and olive-mill
waste water [37], protein production on alkanes [38], and
aroma compound formation from fatty acid derivatives
[39]. When Y. lipolytica is grown on hydrophobic sub-
strates, the cell surface is in direct contact with substrate
droplets and several modifications in cell structure occur,
which are probably related to hydrophobic substrate
transport. These observations have led to the hypothesis
that hydrophobic substrates can migrate through chan-
nels via the plasma membrane to the ER [40,41].
These unique properties of the alkane utilizing yeast Y.
lipolytica together with the availability of efficient gen-
etic tools for this species underscore its potential for
biotransformations in biphasic systems. The yeast Y.
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host for heterologous protein production [42] and sev-
eral CYP genes of mammalian e.g. from Bos taurus and
Homo sapiens s. [20-22], plant e.g. green bell pepper
[43], and fungal origin e.g. Candida maltosa and Rhodo-
torula minuta [44,45], have been expressed in this yeast
so far.
In this study, we report the first example of functional
co-expression of genes encoding the important human
liver CYPs CYP2D6 or CYP3A4 together with hCPR and
intrinsic YlCPR in Y. lipolytica and their use in biphasic
whole-cell bioconversions aiming at steroid oxidation
and as a model for the hydroxylation of other poorly sol-
uble substrates.
Results and discussion
Cloning and expression of genes for human liver
cytochrome P450s and CPRs
One of the most frequently studied bottlenecks in heter-
ologous gene expression is the variable codon-usage and
-bias of different organisms. By exchanging rare codons
with more frequently used ones of the host, the expres-
sion of heterologous genes can be significantly improved
in some cases [46]. In some cases, however native genes
provided better results than codon optimized variants.
In this study, we compared expression of wild-type andcloning
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Figure 1 Schematic representation of construction of the co-expressi
overlap extension PCR fragments into the multicopy integrative vector p64codon optimized genes for CYP2D6, CYP3A4 and
human CPR in Y. lipolytica.
Using Y. lipolytica, it is possible to create multicopy in-
tegration clones employing the auxotrophic marker ura3
linked to a largely truncated and deficient promoter
[47,48]. This approach previously allowed the human
CYP1A1, YlCPR and bovine CYP17 gene expression to
be increased several fold [22,49,50].
In a similar approach, the genes encoding CYP2D6,
CYP3A4, human cytochrome P450 reductase (hCPR)
and Y. lipolytica cytochrome P450 reductase (YlCPR)
were cloned and ligated into (i) the integrative plasmid
vector p64D-linker for selection of multicopy transfor-
mants, as well as into (ii) p65D-linker promoting single
copy integration. The resulting series of expression vec-
tors contained each of the two expression cassettes
under the control of the ICL1 promoter (pICL1D) and
terminator (ICL1t), one for CYP and one for CPR. Y.
lipolytica H222-S4 was transformed with the resulting
SacII (Figure 1) linearized plasmids.
Copy numbers of selected clones were verified by RT-
PCR. Supposed single copy transformants indeed showed
one integrated copy, while multicopy transformants
showed between 10 and more than 40 integrated copies
(Table 1) as determined by quantitative PCR, which is in
good accordance with previous results [20,22,47,48,51]. 
I 
p64ICL1CR 
AscIpICL1D CYP
CCGCGCGGTTTT
ICL1t
on vector. Construction of multicopy coexpression vectors by inserting
D-linker containing the multicopy selective ura3d4 marker.
Table 1 Used Strains and their expression plasmid copy number determined by RT-PCR
Strains Description Copy number Reference
H222-S4 MATA ura3-302a [76]
(Ura-, Alk+, Tgl+, Lip+, Eth+, Glu+,Suc+)
YL23 H222-S4 transformed with SacII – linearized p65D-linker plasmid, negative control This work
YL21 H222-S4 transformed with SacII - linearized p64D-hCPRwt-2D6syn plasmid 46 ± 4 This work
YL10 H222-S4 transformed with SacII - linearized p64D-hCPRsyn-2D6syn plasmid 30 ± 3 This work
YL22 H222-S4 transformed with SacII - linearized p64D-hCPRwt-3A4syn plasmid 23 ± 2 This work
YL11 H222-S4 transformed with SacII - linearized p64D-YlCPR-2D6syn plasmid 26 ± 2 This work
YL18 H222-S4 transformed with SacII - linearized p64D-YlCPR-3A4syn plasmid 10 ± 1 This work
YL15 H222-S4 transformed with SacII - linearized p65D-hCPRwt-2D6syn plasmid 0.9 ± 0.1 This work
YL20 H222-S4 transformed with SacII - linearized p65D-hCPRwt-3A4syn plasmid 1.1 ± 0.1 This work
YL12 H222-S4 transformed with SacII - linearized p65D-YlCPR-2D6syn plasmid 1.1 ± 0.1 This work
YL19 H222-S4 transformed with SacII - linearized p65D-YlCPR-3A4syn plasmid 1.1 ± 0.1 This work
a ura3-302: URA3 disrupted by a construct pXPR2 SUC2 (invertase gene from S. cerevisiae). This allele confers the ability to grow on sucrose or mollasses [76,77].
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duction and the expression phase of microbial cell cultures
can be beneficial for heterologous protein production,
both in terms of a reduced metabolic burden and limita-
tion of a potentially harmful toxic activity. Therefore, Y.
lipolytica was first grown in YNB medium with glucose as
a sole carbon source (YNBG). Upon depletion of glucose
and a short starvation phase, heterologous protein pro-
duction in shake flasks was initiated by induction of the
ICL1 promoter with addition of ethanol. After a short lag
phase, while switching from glucose to ethanol, a further
increase in biomass was observed (Figure 2). Bufuralol
and progesterone were used to assess CYP2D6 and0
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Figure 2 CYP activity and Y. lipolytica biomass production during ind
(6β-hydroxyprogesterone formation, B) activity during ethanol induction of
incubated at 28°C and induced by ethanol after glucose depletion. The Ro
with glucose; II) induction phase of about 70 h. Squares highlight biomass
CYP expression levels measured as specific whole-cell activity. Experiments
4,8,21,26,31,45,50,55 and 69 h.CYP3A4 activity, respectively. Already after 4 to 8 h of in-
duction, Y. lipolytica cells harboring CYP genes showed
activity towards bufuralol or progesterone, the specific ac-
tivity did not further increase and remained constant for
70 h (Figure 2). For practical reasons all further experi-
ments were carried out with cells harvested after 26 h of
induction.
To confirm expression of heterologous cytochrome
P450s, microsomal protein of each clone sampled after
26 h of ethanol induction were analyzed by Western
blotting. Bands of CYP2D6 (~ 55 kDa) and CYP3A4 (~
57 kDa) were detected at the correct sizes. No Western
blots were performed for CPR, since strong protein0
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uction. CYP2D6 (1’-hydroxybufuralol formation, A) and CYP3A4
Y. lipolytica strains YL21 and YL22, respectively. The cultures were
man numerals indicate the following process phases: I) batch growth
concentrations determined as cell dry weight, while bars document
were performed in triplicates. Samples were taken after
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YlCPR (~ 85 kDa) were already detectable by Ponceau-
staining of the blots for multicopy transformants, indi-
cating the high expression levels of CPR. (Figure 3).
Human liver cytochromes P450 2D6 and 3A4 and
human cytochrome P450 reductase (hCPR) as well as Y.
lipolytica cytochrome P450 reductase (YlCPR) were
functionally expressed. The codon optimized versions of
either CYPs showed best activities in combination with
wild-type human CPR and wild-type Y. lipolytica CPR
(data not shown). Therefore, these combinations were
used for Western blot analysis and further used through-
out this study.
For both CYP2D6 and CYP3A4, the use of the p64D-
derived multicopy integration vectors led to a significant
increase of expression (Figure 3) and whole-cell CYP ac-
tivity compared to single copy integrants. CYP2D6 multi-
copy gene integration gave~ 70 fold increase of activity
towards bufuralol, and multiple copies of the CYP3A4
coding sequence resulted in a ~ 50 fold increased activity
towards progesterone (Figure 4). This increase was simi-
lar to that observed by overexpressing a CYP1A1 gene in
the Y. lipolytica strain PO1d [22]. The highest expression M    1     2    3     4     5     6    7 kDa
100
70 
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Figure 3 Western blot analysis. Western blot analysis of
microsomes isolated after 26 h of ethanol induction from cultures of
Y. lipolytica H222-S4 transformed with p64D- or p65D-based
integrative vectors, containing different combinations of CYPs and
CPRs. Protein transfer was monitored by Ponceau S (*) staining,
where putative CPR-protein bands in multicopy transformants were
already visible. CYP-protein bands CYP2D6 (A) and CYP3A4 (B) were
immunodetected with anti CYP2D6 and CYP3A4 antibodies,
respectively.– CYP2D6 was detected in single copy clones (sc) YL12
and YL15 expressing YlCPR-WT+ 2D6syn (1), hCPR-WT+ 2D6syn (2)
respectively and multicopy clones (mc) YL11, YL10 and YL21
expressing YlCPR-WT+ 2D6syn (5), hCPRsyn+ 2D6syn (6), hCPR-
WT+ 2D6syn (7) respectively. CYP3A4 was detected in single copy
clones (sc) YL19 and YL20 expressing YlCPR-WT+ 3A4syn (1),
hCPR-WT+ 3A4syn (2) respectively and multicopy clones (mc) YL18
and YL22 expressing YlCPR-WT+ 3A4syn (5), hCPR-WT+ 3A4syn (6)
respectively. YL23 clone harboring empty p65D-linker vector (3 + 4 in
both panels) was used as negative control. PageRuler Prestained
Protein Ladder (M) was used for monitoring protein separation and
transfer efficiency.levels assessed by CO-spectra for human liver cyto-
chrome P450 2D6 and 3A4 were 92.3 ± 9.2 and 60.9 ± 5.9
pmol per mg microsomal protein, respectively. No results
from CO spectra have been reported for CYP1A1 expres-
sion in Y. lipolytica. Expression levels in the range of 90
and 51–250 pmol per mg microsomal protein have been
reported for CYP2D6 and CYP3A4 in bakers yeast, re-
spectively [12,52,53].Coexpression of CYPs and CPRs
It has been shown that the coexpression of a functional
CPR is important for optimal CYP activity [54,55]. In
some cases the proteins of the native electron transfer
chain can be replaced by other proteins. For example, the
adrenodoxin homologue of Schizosaccharomyces pombe
etp1fd was shown to be able to replace mammalian adre-
nodoxin and transfer electrons from adrenodoxin reduc-
tase to CYP11B1 and CYP11B2 [56]. However, in most
cases the mammalian CPRs are more effective in supply-
ing electrons to mammalian CYPs than other CPRs [57].
This suggests that the intrinsic yeast CPRs may be a lim-
iting factor in the heterologous expression and applica-
tion of mammalian CYPs in yeast. Therefore, we
coexpressed not only the endogenous Y. lipolytica CPR
but also the human CPR.
Cytochrome P450 reductase activity measured as
NADPH cytochrome c reductase activity was detected in
all clones expressing either human CPR or Y. lipolytica
CPR, while a control strain transformed with the empty
vector showed only low endogenous CPR activity. The
multicopy effect described for the hydroxylation activity
was also observed for the CPR activity towards cyto-
chrome c (Figure 4).
Multicopy transformants YL11 and YL18 over-
expressing the endogenous Y. lipolytica CPR showed 7-
fold or 40-fold higher activity towards cytochrome c
compared to multicopy transformants Yl21 and Yl22
over-expressing the human CPR, respectively. This may
be due to a higher affinity of the Y. lipolytica CPR to
cytochrome c as compared to the human CPR. However,
the more likely reason might be the higher YlCPR ex-
pression level, as indicated by the more intense band on
the Western blot when compared to the human CPR
(Figure 3). Despite the higher activity of over-expressed
YlCPR towards cytochrome c, YlCPR coexpression did
yield much lower CYP activities than achieved with
clones coexpressing the human CPR (Figure 4). This
indicates that coupling of the human CYPs with Y. lipoly-
tica CPR, although possible, is inferior to coupling with
human CPR. This is in accordance with earlier results
suggesting that mammalian CPR is more effective in
transporting electrons to mammalian CYPs as compared
to alternative CPRs [3,56,58].
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Figure 4 Influence of copy number and type of reductase on CYP activity. CYP2D6 (A) and CYP3A4 (B) activity of and CPR activities of Y.
lipolytica single-copy and multicopy transformants. Strains coexpressed under pICL1-control the codon-optimized P450 2D6syn (A) or P450
3A4syn (B) in combination with the wild-type human or Y. lipolytica NADPH-P450 reductases (hCPRwt, YlCPR) from integrated single-copies or
multiple vector copies as indicated, except the control strain YL23 on the left in A and B, containing only one endogenous chromosomal YlCPR
copy, which is present as background in all strains. Cultivation at 28°C in YNBG on glucose, induction by 1% ethanol, microsomes isolation,
whole-cell CYP activity and cytochrome P450 reductase (CPR) activity (determined as NADPH-cytochrome c reductase, NCR) measurements were
performed as described in Materials and Methods. Filled bars, CPR activity; hatched bars, CYP activities; -, no genes; + genes in single copy;
++ genes in multicopy.
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Figure 5 Whole-cell hydroxylation of different steroids. Whole-
cell hydroxylation of different steroids in aqueous phase system,
employing Y. lipolytica YL21 and YL22 cells harboring CYP2D6 (filled
bars) or CYP3A4 (striped bars), respectively. Data is shown as activity
relative to the highest measured apparent hydroxylation rate of
testosterone (3.9 ± 0.1 mU per g CDW). Compounds were converted
by cells equivalent to ~ 10 g/L CDW for 16 hours. Activity was
determined in test tubes as product formation rate after adding
steroids dissolved in DMSO to a final concentration of 2 mM.
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Resting and growing whole-cells can be employed as cat-
alysts for biotransformations. Growing cells are consid-
ered more favorable than resting-cells when expressing a
protein with low stability, since they permit sustained
protein expression during biotransformation. However,
resting-cells have the advantage that the desired reaction
can be investigated independently of growth phenomena
and at higher cell densities. Furthermore, biotransform-
ation conditions can be chosen independently from
growth conditions minimizing side reactions and allow-
ing identification of potential limitations [59].
Differences between growing and resting cells on
bufuralol and protesterone hydroxylation rates were
investigated for Y. lipolytica harboring hCPR combined
with CYP2D6 and CYP3A4, respectively. The hydroxyl-
ation rates were determined as product formation rates
measuring the concentrations of hydroxybufuralol or
hydroxyprogesterone, respectively. Resting-cells showed
significantly higher hydroxylation rates than growing
cells (data shown in Additional file 1). Therefore,
resting-cells were used further in this study.
Both CYP2D6 and CYP3A4 have also been tested
for their ability to hydroxylate testosterone, 17-alpha-
methyltestosterone and progesterone. CYP2D6 usually
prefers substrates containing a basic amine function
[3]. Nevertheless, some studies have shown that
CYP2D6 is also involved in steroid hydroxylation
[60,61]. Both recombinant human liver cytochrome
P450 whole-cell Yarrowia catalysts hydroxylated testos-
terone, 17alpha-methyltestosterone and progesterone(Figure 5). Although expression levels have been lower
for CYP3A4 compared to CYP2D6, Y. lipolytica cells
harboring CYP3A4 and hCPR in all cases showed the
expected several-fold higher activity towards steroids,
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formed control strain YL23 showed no formation of
any hydroxylated steroid. However, Y. lipolytica is oxi-
dizing the hydroxy function of testosterone at position
17 to the corresponding keto-function giving andro-
stenedione [62,63]. Such undesired side reactions may
hamper the reliability of activity measurements. There-
fore, testosterone was excluded and progesterone, an-
other known standard substrate for CYP3A4, was used
for bioconversion studies. Furthermore, progesterone
was used to investigate the potential of two-liquid bi-
phasic systems and Y. lipolytica catalysts for more effi-
cient whole-cell bioconversions.
Whole-cell conversion in biphasic systems
Most of the typical human liver CYP substrates are very
hydrophobic. Hence, one main function of CYPs is to in-
corporate a hydroxyl function to render the compound
more water soluble and to activate it for further metabo-
lization. Alkane-utilizing yeasts, such as Y. lipolytica, can
excrete surfactants and adjust their cell surface and cell
wall to directly interact with water immiscible organic
substrates, like alkanes, long-chain fatty acids and trigly-
cerides, facilitating their uptake [40,41,64-67]. These
properties as well as metabolic adaptations and the sub-
cellular organization of the alkane-utilizing yeast cell are
obviously supporting the high in vivo turnover numbers
observed for the host-own P450s of the CYP52 family
involved in primary alkane and fatty acid oxidation
[40,41,67-69].
In this study, we investigated whether the unique prop-
erties of Y. lipolytica will support also the function of
heterologously expressed CYPs in this yeast and will give
this organism an advantage in CYP-catalyzed bioconver-
sion of hydrophobic substrates dissolved in organic sol-
vents. A spectrum of 10 water immiscible organic
solvents ranging from (i) solvents with known good solv-
ent properties (toluene, 1-octanol), (ii) inert fluids (bis-
ethyl hexyl phthalate, dibutyl phthalate) to (iii) potential
carbon sources (1-decanol, 1-dodecanol, methyl laureate,
ethyl oleate, n-decane, n-dodecane) [70,71] were chosen.
The solvents toluene and 1-octanol, which are known to
be toxic for microorganisms, enabled the highest solubil-
ity of steroids. Indeed, they showed the expected toxic ef-
fect on Y. lipolytica cells, too. Two solvents, known to be
utilized as a carbon source by Y. lipolytica, n-decane and
n-dodecane, conferred very low solubility of progester-
one and were therefore excluded from further analyses.
1-decanol, 1-dodecanol, methyl laureate, ethyl oleate,
bisethylhexylphthalate (BEHP) and dibutyl phthalate
(DBP) had no obvious toxic effects and enabled reason-
able solubility of steroids (Additional file 2).
As mentioned before, exposing Y. lipolytica cells to
water immiscible organic solvents triggers changes incell structure resulting in increased hydrophobicity [66].
Even when the organic solvent is not utilized by Y. lipo-
lytica, morphological changes of the cells immediately
become obvious. The cell suspensions become less
homogenous and cell agglomerates form. It has been
reported that significant changes to the cell surface
(increased cell wall hydrophobicity, occurrence of pro-
trusions and special channel like structures) are import-
ant for the cells to attach to the hydrophobic substrates
as well as for the uptake of these substrates
[40,41,66,72,73]. Y. lipolytica was observed to adsorb to
the organic solvent droplets of DBP and ethyl oleate,
similarly to the previously observed adsorption to hexa-
decane when cells are grown in media containing that
alkane as sole carbon source [40,41].
Based on the experiences with aqueous whole-cell bio-
conversions, biotransformations in biphasic systems also
were performed with resting-cells. Cells were taken after
26 h of ethanol induction and resuspended in 100 mM
potassium phosphate, pH 7.4, containing 1% w/v glucose
to a biomass concentration of ~ 12 g/L CDW. The cell
suspension was then mixed with an equal volume of the
organic phase containing 20 mM of progesterone. Con-
versions were performed at 30°C over night while shak-
ing. All data were calculated with respect to the aqueous
phase volume. Based on other reported experiences [24]
for conversion in aqueous systems steroids were added
above their solubility limit as DMSO stock solution
resulting in precipitation of most of the hydrophobic
substrate. Surprisingly, most of the tested water immis-
cible organic solvents led to a decrease in conversion
rate of at least 50% compared to the pure aqueous sys-
tem where just the organic solvent of the pre-solubilized
substrate was added. Only ethyl oleate enabled a slightly
increased conversion rate (Figure 6).
Thus, ethyl oleate was identified as the most promis-
ing water immiscible organic solvent for the biphasic
conversion of progesterone in shake flask cultures. Com-
paring one utilizable and one non degradable organic
solvent, ethyl oleate and dibutyl phthalate [Mauersberger
et al. unpublished results][74], respectively, were chosen
to perform bioconversions under more controlled condi-
tions in bioreactors.
Two-liquid phase bioreactor process
Biphasic and aqueous bioconversions of progesterone
with recombinant Y. lipolytica catalysts harboring
CYP3A4 and hCPR have been performed in a stirred
tank bioreactor. For biomass production, a standard
batch was run for 16 h (phase I) followed by a fed-batch
run for 10 h at a constant growth rate of μ= 0.18/h
(phase II). Subsequently CYP3A4 and hCPR production
was induced by a low, linearly increasing feed of ethanol
over 36 h (phase III). Samples were taken at different
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Figure 6 Whole-cell conversions of Y. lipolytica in biphasic
conditions. Comparison of whole-cell conversion with resting Y.
lipolytica YL22 cells harboring CYP3A4 and hCPR in aqueous (striped
bar) and biphasic systems (filled bars) using different organic
solvents as 2nd phase. Activity was determined as product formation
rate.
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Figure 7 Biomass and CYP3A4 activity during cultivation of
Y. lipolytica YL22 in bioreactor. Time course of biomass
concentration and volumetric whole-cell CYP3A4 activity determined
during fed-batch cultivation and ethanol induction. Open symbols,
biomass concentration determined as cell dry weight; closed
symbol, CYP3A4 expression levels measured as volumetric whole-cell
activity of 6beta-hydroxyprogesterone formation determined by
separate activity assays in test tubes. The Roman numerals show the
following process phases: I) batch growth with glucose; II) fed-batch
growth over 10 h with exponential addition of glucose at an
exponentially increasing feed rate; III) induction phase of about 36 h
with a low linear addition of ethanol.
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mation was determined in test tubes. Interestingly, a low
CYP activity was already observed during fed-batch
(phase II) on glucose. This reflects a derepression of the
pICL1 promoter under conditions of glucose limited
growth or glucose depletion. The highest specific 6-beta-
hydroxyprogesterone activity of 22 mU/g CDW was
reached after roughly 12 h of ethanol-induction and
remained constant during the induction time. However,
the highest volumetric progesterone hydroxylation rate
of 1 U/L (calculated from the specific activity) was
reached after roughly 24 h of induction (Figure 7). Cells
were harvested after 36 h of induction and resuspended
in glucose containing potassium phosphate buffer to a
biomass concentration of ~ 25 g/L CDW. Aqueous and
biphasic bioconversions in 1.5 L stirred tank reactors
used the same cell suspension as starting material. Glu-
cose at a low constant feed of 0.007 g/h/g CDW com-
pared to exponential feed of 1.05 g/h/g CDW during fed
batch, was provided as energy source for cell mainten-
ance and regeneration of cofactors.
During the first hour in both biphasic systems less
hydroxyprogesterone was formed than in the aqueous
system. As of 2 hours of conversion the ethyl oleate
based biphasic system provided the highest conversion
rates (Figure 8). However, after 6 h the product formation
rate of all systems started to drop significantly. While the
product formation of the aqueous system came even
nearly to a halt after 6 h. The product formation of bothbiphasic systems continued at a reduced rate throughout
the whole biotransformation experiment (Figure 8).
In the beginning of the bioconversion of the different
systems the substrate is probably taken up directly from
the aqueous phase. The discrepancy in the hydroxylation
rate of the different bioconversion systems in this early
phase of conversion, is likely due to the difference in
availability of progesterone in the aqueous phase. Indeed,
for ethyl oleate 8 times and for dibutyl phthalate 42
times higher concentration of progesterone were mea-
sured in the aqueous system compared to the aqueous
phases of the respective biphasic system. The available
substrate concentrations in the aqueous phases stayed
more or less constant during the whole bioconversion
process excluding the influence of partitioning of sub-
strate on observed variations of bioconversion rates dur-
ing the conversion process. Y. lipolytica cells most
probably need some time to adjust to the new hydropho-
bic environment. This seems to be significantly faster for
the naturally occurring utilizable ethyl oleate giving
much faster product formation compared to the inert
non degradable dibutylphthalate. The generally lower
conversion rates in biphasic systems might be explained
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Figure 8 Hydroxyprogesterone formation during whole-cell conversion in bioreactor. Time course of hydroxyprogesterone formation
during whole-cell conversion of progesterone by Y. lipolytica YL22 cells harboring CYP3A4 and hCPR. Closed triangles: aqueous phase system;
open circles: with dibutylphthalate (DBP) as second organic phase; open squares: with ethyl oleate as second organic phase.
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in presence of organic solvents.
Subsequently, the uptake of bioconversion substrate
may be achieved in different ways; either Y. lipolytica
cells continue to take up the low concentrations of sub-
strate from the aqueous phase, or a direct uptake of sub-
strate from the organic phase takes place. Although, the
ethyl oleate might be cleaved by secreted lipases, the
most reasonable explanation would be the co-uptake of
ethyl oleate and dissolved steroid, similarly to the alkane
uptake. In such a case, the conversion rate might be lim-
ited by the uptake rate of the organic phase.
Although dibuthylphtalate was shown to be a very well
suitable substrate for the conversion of hydrophobic
substrates in biphasic system using another alkane utiliz-
ing yeast [75], in our study dibutyl phthalate as second
phase enabled significantly lower conversion rates com-
pared to ethyl oleate.
After approximately 1.5 and 43 h, the overall product
formation of both, the ethyl oleate and DBP biphasic
systems, respectively, exceed the aqueous system, with
an ongoing catalyst activity within the evaluated period
of 100 h of bioconversion. However, it was observed
that surprisingly the use of DBP as organic phase also
lead to a significant change in the product profile
formed from progesterone, while ethyl oleate did not.
Already after 2 h there is a discrepancy in the hydroxyl-
ation pattern in the dibutyl phthalate biphasic system,
compared to the aqueous and the ethyl oleate biphasic
system. One might speculate that a different extent of
emulsification and transport effects in different solvent
systems might contribute to this effect. However noexperiments were performed to proof this hypothesis.
At the beginning, 6-beta-hydroxylation is dominant.
However, the hydroxylase specificity is shifted to the
formation of an unknown hydroxy product. After
roughly 4 hours, the hydroxylase rate towards the un-
known position exceeds the rate towards the 6-beta-
position. At the end of the two-liquid phase bioreactor
experiment the hydroxylation pattern is considerable
shifted. The unknown product makes up 65% of the
total product compared to only traces in aqueous system.
By comparing the unknown product to in-house available
hydroxyprogesterone standards 6-beta, 11-alpha, 16-
alpha and 17-alpha hydroxyprogesterone, we were not
able to identify the new product. Unfortunately the con-
centration was not high enough to identify the product
by other means e.g. NMR.
Oleate esters naturally occur in the membranes of Y.
lipolytica. They are incorporated into lipids or degraded
as energy source and might show less influence on cellu-
lar membranes or membrane bound proteins than dibu-
tyl phthalate which is not degraded by Y. lipolytica.
Furthermore, DBP is more similar to steroids and may
enter the binding pocket of CYP3A4 which might ex-
plain the distorted hydroxylation patterns.
Conclusion
The Y. lipolytica strain H222-S4 was engineered to ex-
press the human liver CYP2D6 and CYP3A4. Co-
expressing human cytochrome P450 reductase as well as
increasing the copy numbers of both genes improved
the catalytic performance of these whole-cell biocata-
lysts. However the human CYP reductase was the more
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findings, stating that not only human CYP3A4 but to
some extent also CYP2D6 is able to hydroxylate steroid
molecules such as testosterone, 17α-methyltestosterone
and progesterone which are non-typical CYP2D6
substrates.
By using bio-degradable ethyl oleate in a two-liquid bi-
phasic setup instead of aqueous systems, we could show
that Y. lipolytica cells harboring human CYP3A4 and
human CPR can be applied as a whole-cell system with
increased biocatalytic stability. This might be caused by
different cellular adaptation mechanisms to the organic
compounds such as cell wall adaptation or by different
transport mechanisms. A systems biology approach
might help to clarify these issues, which was out of
scope of this study. As expected the alkane-assimilating
yeast Y. lipolytica, coupled with above described expres-
sion strategies, demonstrated to be promising tools for
biotransformations of hydrophobic substrates in two-
liquid biphasic systems. Especially organic solvents
which can be efficiently taken up and/or metabolized by
the cell might enable more efficient bioconversion as
compared to aqueous systems and even enable simple,
more stable, continuous or at least high yield long time
processes.
Materials and Methods
Chemicals and reagents
Unless stated otherwise, all chemicals were purchased from
BD Bioscience (USA), Sigma–Aldrich (Germany), Carl Roth
GmbH (Germany), J.T. Baker (Netherlands) and Roche
Diagnostics (Germany) at the highest purity available. Oli-
gonucleotides were purchased from IDT (Belgium).
Strains, media and culture conditions
E. coli Top10 or E. coli Top10F’ (Invitrogen Corp.)
strains were used as host for recombinant plasmid
propagation. Cells were grown on Luria-Bertani Agar
(Carl Roth GmbH) supplemented with 100 μg/mL ampi-
cillin at 37°C. DNA isolation and purification was done
using Fermentas Miniprep kit or Promega Wizard SV
Gel isolation and PCR cleanup kit.
In this study, the Y. lipolytica strain H222-S4 (MATA
ura3-302) [76] was used as recipient strain for integration
of plasmids described in Table 2. The Y. lipolytica strains
were grown at 28°C on solid complete medium YPD or
on minimal medium YNB (Difco, BD Biosciences, USA)
supplemented with 2% w/v glucose (YNBD) and 15 g/L
agar [48]. Transformants were selected on solid YNBD
(15 g/l agar). Cultivation in liquid media was performed
with 200 or 250 mL of buffered minimal YNB medium
supplemented with 0.6% w/v glucose and 200 mM potas-
sium phosphate buffer, pH 6.5, in 1 L Erlenmeyer flasks at
28°C.All seed and inoculum cultures were prepared using
buffered minimal medium YNB (Difco) supplemented
with 1% w/v glucose and 200 mM potassium phosphate,
pH 6.5. The defined mineral medium used for the main
fed-batch cultures contained per liter.
6.0 g (NH4)2SO4, 2.0 g KH2PO4, 0.24 g K2HPO4, 1.4 g
MgSO4 x 7 H2O, 0.6 g NaCl, 0.58 g NaNO3, 0.38 g CaCl2,
1 mL PTM trace element solution, i.e. 0.5 g/L H3BO3,
0.04 g/L CuSO4 x 5 H2O, 0.1 g/L KI, 0.303 g/L MnSO4 x
1 H2O, 0.2 g/L Na2MoO4 x 2 H2O, 0.4 g/L ZnSO4 x 7
H2O, 0.2 mL of ethanolic iron chloride solution i.e.
30 g/L FeCl3 x 6 H2O, 1 mL thiamin hydrochloride
solution i.e. 4 g/L and 16.5 g glucose monohydrate.
The feed solution contained 550 g glucose monohy-
drate per liter, 3 mL PTM trace element solution,
0.2 mL ethanolic iron chloride solution and 3 mL thia-
min hydrochloride solution.
For induction of the pICL1-controlled CYP expression,
pure ethanol was used as feed solution.
Genes and vectors
The integrative multicopy and single copy Y. lipolytica
vectors p64ICL1, p65ICL1 [51,77,78] were adapted by
replacing the ICL1 intron and gene with a small linker
containing SpeI and AscI restriction sites and used for
cloning and co-expressing CYPs and CPRs. The vector
p67RYL was used to isolate the Y. lipolytica CPR gene
which is essentially the wild-type gene but alanine at
position 2 was chanced to proline [48,79,80]. pNMTS-
CYP-OR-spe and pBdpTrcRed-3A4(192v)wtA305S were
used to isolate codon optimized human CYP3A4 and
codon optimized human CPR gene, respectively. Both
were optimized for expression in yeast, i.e. hybrid opti-
mized for P. pastoris, S. pombe and S. cerevisiae (Weis
et al., unpublished).
Wild-type human CYP2D6 (ID30915411), wild-type
human CYP3A4 (ID7262313) and wild-type human CPR
(ID3882411) genes were isolated from cDNA clones
(BioCat GmbH, Germany).
For the codon optimization of the CYP2D6 gene, the
free software “Gene Designer V1.1.4.1” (DNA 2.0, USA)
was used to design a gene optimized for expression in
yeast, i.e. hybrid optimized for P. pastoris and Y. lipoly-
tica, and then synthesized.
Vectors constructions
For vector construction, standard molecular biology pro-
cedures were performed [81]. The multicopy vector
p64D-linker and single copy vector p65D-linker were
obtained by replacing the isocitric lyase 1 (ICL1) gene
and intron with a linker containing SpeI and AscI site, in
the parental vectors p64ICL1 and p65ICL1, respectively.
Both vectors contain the URA3 selection marker. The
p64-vector variants contain a deficient, truncated
Table 2 Plasmids used
Plasmid Description Marker gene
(selection in yeast)
Reference
p64ICL1 Parental vector for multicopy integration in Y. lipolytica ura3d4 (mc)a [51]
p65ICL1 Parental vector for single copy integration in Y. lipolytica ura3d1 (sc) a [51]
p67RYL Source for Y. lipolytica cytochrome P450 reductase (YlCPRwt) ura3d4 (mc)a [22,49]
pNMTS-CYP-OR-spe Source for codon optimized human cytochrome
P450 3A4 (3A4syn)
Weis et al., unpublished
(IMBT, TU Graz)
pBdpTrcRed-3A4(192v)wtA305S Source for codon optimized human cytochrome P450
reductase (hCPRsyn)
Weis et al., unpublished
(IMBT, TU Graz)
ID7262313 Source for cDNA wild-type human cytochrome P450
reductase (hCPRwt)
BioCat, Germany
Cloning vectors:
pJet1.2 E. coli cloning vector Fermentas, Germany
p64D-linker Cloning and basic integrative multicopy vector ura3d4 (mc) a This work
p65D-linker Cloning and basic integrative single copy vector,
negative control
ura3d1 (sc) a This work
Integrative vectors for CPR and CYP expression in Y. lipolytica:
p64D-hCPRwt-2D6syn Multicopy coexpression of human
wild-type CPR (hCPRwt),
codon optimized CPR (hCPRsyn) or Y.lipolytica-own
CPR (YlCPR) in combination with codon optimized
CYP2D6 or codon optimized CYP3A4, respectively.
ura3d4 (mc) a This work
p64D-hCPRsyn-2D6syn
p64D-hCPRwt-3A4syn
p64D-YlCPR-2D6syn
p64D-YlCPR-3A4syn
p65D-hCPRwt-2D6syn Single copy coexpression of human
wild-type CPR (hCPRwt)
or Y. lipolytica-own CPR (YlCPR) in combination
with codon optimized CYP2D6 or codon
optimized CYP3A4, respectively.
ura3d4 (mc) a This work
p65D-hCPRwt-3A4syn
p65D-YlCPR-2D6syn
p65D-YlCPR-3A4syn
a URA3 marker genes for single copy (sc, ura3d1) or multicopy (mc, ura3d4) selection with different promoter lengths.
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gives only sufficient amounts of gene product when sev-
eral copies (at least 8–10) of the vector are integrated
into the genome. This allows for selection of clones with
multicopy integrations or gene multiplications. The p65-
vector variants contain the ura3d1 promoter sufficient
for single copy selection [47,48].
Co-expression of single and multicopy vectors with
combinations of different CPRs and cytochrome P450s
were obtained by cloning overlap extension PCR products
into the SpeI and AscI sites (Figure 1). Each gene was
placed under the control of the ICL1 promoter [82].
Shortly; each fragment, i.e. CPR, ICL1 promoter and ter-
minator, CYP was amplified via PCR using primers with
overhangs homologous to adjoining parts. Overlap exten-
sion PCR was done in two steps. All fragments were added
to the first reaction mix PCR was run for 20 cycles using
Phusion Polymerase (NEB). Then flanking primers were
added to the reaction which was run for another 25 cycles
to amplify the overlap construct. The fuel-length PCR con-
struct was then cloned into pJet1.2 using the CloneJET™
PCR Cloning Kit (Fermentas) and verified by sequencing(LGC genomics, Germany). Confirmed inserts were cloned
with SpeI/AscI into p64D-linker or p65D-linker, respect-
ively, using T4 DNA ligase (Fermentas) according to
standard procedure.
Transformation into Y. lipolytica
Transformation of Y. lipolytica H222-S4 was performed
by the lithium acetate method [38] or by electroporation
according to a condensed protocol [83]. All vectors con-
tained the rDNA (ribosomal DNA fragment) of Y. lipoly-
tica as integration site and were digested by SacII before
transformation. The transformants were selected for Ura
+ phenotype on minimal YNBD medium (2% w/v glu-
cose). Colonies appearing after 2–3 days (single copy)
and 2–3 weeks (multicopy) were transferred onto fresh
plates and sub-cultured. The resulting prototrophic re-
combinant Y. lipolytica strains used for CYP and CPR
expression and steroid biotransformation studies and
their estimated integrated vector copies are given in
Table 1.
Real-time PCR (RT-PCR) was used to estimate the
copy number of the integrated expression cassettes.
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mants grown overnight in minimal YNB medium sup-
plemented with 1% w/v glucose (YNBD) [84]. The ICL1
set of primers, ICL1-fw (5′-CCA GCA GCC CGA GAT
TGA-3′) and ICL1-rv (5′-ACT CAG CAC CGG ACC
ACT TC-3′), anneal to the single copy of the endogen-
ous Y. lipolytica ICL1 gene within the chromosome. The
Amp primers, Amp-fw (5′-GCT ATG TGG CGC GGT
ATT ATC-3′) and Amp-rv (5′-GTA TGC GGC GAC
CGA GTT-3′), target the ampR marker gene present on
the integrated vectors. Y. lipolytica YL23 was used as a
control organism with a single copy of both the ICL1
and ampR target sequences. Reaction mixes of 18 μl con-
sisted of 100 pg template DNA, Power SYBR Green
Master Mix (Applied Biosystems, CA, USA), and 250
nM of each primer. Each reaction was run in duplicate
in an ABI PRISM 7300 Real Time PCR machine (Ap-
plied Biosystems, CA, USA). The profile used was, 95°C
for 10 min, fallowed by 40 cycles of (95°C for 15 s, 60°C
for 60 s). Data collection was done after each 60°C step.
A melting curve analysis was conducted after the ampli-
fication, heating from 45°C to 95°C. Analysis was done
using Sequence Detection Software SDS (Applied Bio-
systems, version 1.2). Average Ct values of the 2 profiles
(ICL1 and Amp) were used to estimate the relative copy
number for the selected transformant [85].
CPR and CYP induction
Y. lipolytica clones were grown in YNBG (1% w/v glu-
cose) overnight at 28°C and 220 rpm. Exponentially
growing cells were taken to inoculate the YNBG
(0.6% w/v glucose) main culture to a starting OD600 of ~
0.5. The main culture was grown at 28°C and 220 rpm
for 17 – 20 h until glucose was fully consumed. After
additional 2–4 h, the expression of CPR and CYP under
the control of the ICL1 promoter was induced by adding
ethanol to a final concentration of 1% v/v. Additional
1% v/v ethanol was added after ~ 8 h and~ 20 h. After
24 h the cells were harvested by centrifugation and fur-
ther used for either whole-cell biotransformation assays
or microsome isolation.
Isolation of microsomes
Yeast cells were harvested by centrifugation at 2 000 g for
10 min and washed twice with water. 4–6 g of cells were
resuspended in~ 20 ml disruption buffer (50 mM potas-
sium phosphate, pH 7.9, containing protease inhibitor
1 mM PMSF, 5% w/w glycerol, 1 mM EDTA and 2 mM
DTT). A crude cell lysate was obtained by mechanical cell
disruption using “Merkenschlager homogenization” [86].
After cell disruption cell debris was removed by centrifu-
gation at 10 000 g and 4°C for 10 min. To pellet the
microsomal fraction, the supernatant was centrifuged at
100 000 g and 4°C for 1 h. The membrane pellet wasresuspended in disruption buffer to~ 1 mg pellet per mL
using a Dounce homogenizer and pestle.
SDS-PAGE and Western blot analyses
Total protein content of the microsomal preparation
was determined by Bradford using the biorad protein
assay kit (Bio-Rad, Germany) before separating the pro-
teins by using the NuPAGEW electrophoresis system
(Invitrogen Ltd). Samples containing ~ 20 μg total pro-
tein in 15–25 μL loading buffer without reducing agent
were incubated at RT for at least 10 min. For separation,
a NuPAGE Novex 4-12% Bis-Tris-Gel and MOPS buffer
were used. The PageRuler Prestained Protein Ladder
(Fermentas) was used as molecular mass calibration
standard.
Western blotting was done according to the protocol
provided with the MAB-2D6 and WB-3A4 kits (BD
Gentest™). On completion of PAGE, the proteins were
transferred electrophoretically onto nitrocellulose mem-
brane (GE Healthcare Europe GmbH) in a wet blotting
system. Then the membranes were blocked at room
temperature overnight with whey powder. The blot was
developed by incubation with NBT/BCIP at RT for
5 min.
NADPH cytochrome c reductase (NCR) activity
The cytochrome P450 reductase-catalysed reduction of
bovine heart cytochrome c was measured at 550 nm es-
sentially as described [70]. A 300 μM cytochrome c solu-
tion in 50 mM Tris–HCl buffer, pH 7.5, was mixed with
2 to 80 μg of microsomal protein and made up with
Tris–HCl to 650 μL. Fifty μL of 50 mM KCN solution,
pH 7.7, were added to mask cytochrome c oxidase activ-
ity. Reaction was started by adding 50 μL of 1.5 mM
NADPH.
Activities were measured on a UV/Vis DU 800 spec-
trophotometer (Beckman Coulter, USA) and calculated
by using E550nm=21 mM-1 cm-1 as molar extinction
coefficient of cytochrome c.
Quantification of cytochrome P450
CYP concentrations in the isolated microsomes were
determined by reduced carbon monoxide spectra [87].
Six to 12 mg of microsomal protein were added to
100 mM sodium phospate buffer, pH 7.4, containing
20% w/w glycerol to an end volume of 2 mL. One hun-
dred μL 200 mM KCN, pH 7.7, were added to mask the
spectral interference of cytochrome oxidase (negative ab-
sorption at 445 nm) with the CYP peak at 450 nm in the
CO difference spectrum [49]. A few grains sodium di-
thionite were added to reduce the CYP. The mixture
was transferred into polystyrene cuvettes (Sarstedt, Ger-
many) and a reference spectrum was recorded from 400
to 500 nm (Specord 205 UV/Visible spectrophotometer,
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with carbon monoxide for 60 s, and the spectrum was
measured repeatedly several times.
The CYP concentration was calculated using a molar
extinction coefficient of E450nm = 91 mM
-1 cm-1.
CYP activity of microsomes and whole-cells
In vitro substrate conversion with microsomes was per-
formed essentially as described in [88]. Twenty five μM
bufuralol or 2 mM steroid (in DMSO) e.g. progesterone,
17alpha-methyltestosterone or testosterone, and 1 mM
NADPH were added to 100 mM possium phosphate buf-
fer, pH 7.4, and pre-incubated for 2–3 min at 37°C. The
reaction was started by adding 20 μL microsomal prepar-
ation (0.6 to 0.8 mg total protein) to give a total volume
of 200 μL. The reaction mixture was incubated at 37°C
for 20 min (bufuralol) or 1 h (steroid) while shaking and
stopped by adding 20 μL 70% perchloric acid. After
20 min of incubation on ice, prednisolone (in DMSO)
was added to a final concentration of 50 μM as internal
standard and the mixture centrifuged for 10 min at 16
100 g. One hundred μL supernatant were transferred to a
fresh microtiter plate and stored at −20°C.
For whole-cell conversions, yeast cultures were spun
at 2000 g for 15 min and the cell pellets were resus-
pended in 100 mM potassium phosphate buffer, pH 7.4,
containing 1% w/v glucose to a biomass concentration
of ~ 10 g/L CDW. Stock solutions of substrate were
added to 200 (eppendorf tube) or 1000 μL (PYREX
tubes) of cell suspension. Bufuralol was added as 1 mM
stock solution to cell suspension yielding a final concen-
tration of 25 μM. Steroid e.g. progesterone, 17alpha-
methyltestosterone or testosterone was added as
100 mM stock solution in DMSO to cell suspension
yielding a final concentration of 2 mM. Whole-cell con-
version of bufuralol and progesterone was performed at
30°C for 20 – 60 min or several hours while shaking, re-
spectively. Then prednisolone (in DMSO) was added to
a final concentration of 50 μM as internal and the reac-
tion was stopped by centrifugation at 16 100 g for
10 min. Supernatants were transferred to fresh reaction
tubes and stored at −20°C.
CYP activity in whole-cell biphasic systems
Twenty to fifty mL yeast cultures were centrifuged at
2000 g for 15 min and the pellet was resuspended either
in induction media supplemented with 1% v/v ethanol
or in 100 mM potassium phosphate buffer, pH 7.4, con-
taining 1% w/v glucose to a biomass concentration
of ~ 10 g/L CDW. An equal volume of organic solvent
containing 20 mM progesterone, was added to 1000 μL
of cell suspension. The biphasic whole-cell conversions
were performed in 10 mL PYREX tubes at 30°C while
shaking at 320 rpm for several hours. Reactions werestopped at desired time points and the two phases were
separated by centrifugation at 16 100 g for 10 min. Two
to five hundred μL aqueous and organic phase were
transferred to fresh reaction tube or GC-vial, respect-
ively. Prednisolone (in DMSO) was added to a final con-
centration of 50 μM as internal standard. An equal
volume of isopropanol was added to the organic phase,
and samples stored at −20°C.
Fed-batch cultivation in bioreactors
Cultivation process was performed in a 5 L stirred tank
bioreactor (Biostat C, Sartorius, Germany). The initial
batch working volume was 3.5 L (minimal mineral salt
medium M with initial 1.5% w/v glucose) and was
increased to 4 L at the time of harvesting. The set-
points of all control variables were maintained during
the entire process, thus, the cultivations were accom-
plished under the conditions of constant temperature of
28°C, 10 L/min air flow (i.e. without any oxygen enrich-
ment), 1500 rpm agitation, pH 5.5. Automated control
of the pH was achieved by using 25% ammonia and 25%
phosphoric acid solutions. The process consisted of the
biomass growth phase on glucose, i.e. batch and expo-
nential fed-batch cultures, and the expression phase on
ethanol with linear feed addition. The cultivation started
at time 0 h with a batch (1.5% w/v glucose) during which
the pO2 value continuously decreased and the base con-
sumption increased, i.e. no control of the pO2 set-point
was applied. After 14–16 h, the pO2 increased rapidly
and base consumption stopped due to glucose depletion.
At this point the exponential addition of glucose feed so-
lution was started and continued over 10 h according to
the function f(t) = 1.05*e0.18*t in grams of glucose per
hour. During the subsequent production phase, 0.5% v/v
ethanol was maintained for 34–36 h in accordance with
the function f(t) = 1.05*e0.002*t in grams of ethanol per
hour. Biomass concentration was determined by measur-
ing cell dry weight (CDW) e.g. 2 mL cell suspension was
centrifuged at 16 000 g for 10 min. Supernatant was
discarded and cell pellet dried at 100°C till constant
weight. Cells where harvested by centrifugation at RT
and 2 000 g for 15 min and cell pellets were resuspended
in 100 mM potassium phosphate buffer, pH 7.4, supple-
mented with 0.5% w/v glucose as energy source to a
desired biomass concentration of ~ 25 g/L CDW.
Resting-cell biotransformation in bioreactor
Biotransformations were performed in a 1.5 L stirred
tank bioreactor (DASGIP Parallel Bioreactor Systems,
DASGIP BioTools, Germany). The batch working vol-
ume was 600 mL (phosphate buffer with glucose and
ethanol-induced Y. lipolytica cells as indicated above)
for aqueous phase system and 450 mL aqueous phase
plus 150 mL organic phase for biphasic systems. The
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ing the entire biotransformation at 30°C, 1 NL/min air-
flow (i.e. without any oxygen enrichment), 500 rpm
agitation and pH 7.4.
The transformations began at 0 h by adding 100 mM
progesterone stock solution (in DMSO) to a final con-
centration of 2 mM or 150 mL water immiscible organic
solvent containing 20 mM progesterone. Glucose was
provided at a low constant rate of 0.17 g h-1 over the en-
tire biotransformation time of 90 hour. Samples were
taken at different time points and the reaction was
stopped removing the cells by centrifugation at 16 100 g
for 10 min. Aqueous and organic phase samples were
withdrawn as described above.
Analysis by HPLC-MS
Bufuralol and metabolites were separated by HPLC
(1200 series, Agilent technologies, USA) with a XDB-
C18, 1.8 μm, 4.6 x 50 mm column (Agilent technologies,
USA) using a gradient based on 10 mM ammonium
acetate, pH 5.5, and acetonitrile at a flow rate of 0.9 mL/
min. Metabolites were detected using MSD SL detector
equipped with an electron spray ionization (ESI) unit
(Agilent technologies, USA).
Hydroxylated products were quantified by external cali-
bration using reference metabolites or metabolite derivates.
Steroid metabolites were separated by HPLC (1200
series, Agilent technologies, USA) with a Chromolith
RP-C18e, 5 μm, 4.6 x 100 mm column (MERCK KGaA,
Germany) using a gradient based on water and aceto-
nitrile, both acidified with 0.1% v/v acetic acid, at a flow
rate of 1 mL/min.
Additional files
Additional file 1: Influence of growth phase on whole-cell
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Additional file 2: Solubility of progesterone in organic solvents.
Solubility of progesterone in the different organic solvents shown
as a diagram.
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